Posted under Venture Capital
from 1810 days ago

Adrian Senderowicz has joined Tokai Pharmaceuticals Inc. as chief medical officer and vice president, medical development. Senderowicz was previously senior medical director of oncology clinical development at AstraZeneca. Privately held Tokai is based in Cambridge, Mass., and is backed by Apple Tree Partners and Novartis Venture Fund.

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the appointment of Adrian M. Senderowicz, M.D., to the position of chief medical officer and vice president, medical development. Dr. Senderowicz brings 15 years’ experience as a board-certified medical oncologist with significant industry, clinical, academic and U.S. regulatory expertise. Tokai’s lead candidate, galeterone (TOK-001), recently received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of metastatic castration-resistant prostate cancer (CRPC), an advanced and difficult-to-treat form of prostate cancer that occurs when the disease progresses ...


blog comments powered by Disqus
Editor's Pick
Popular Today